Nancy Wysenski joins Inovio Pharmaceutical board

Nancy Wysenski recently joined the board of directors of Inovio Pharmaceuticals, which develops immunotherapies to treat infectious diseases and cancers.

Wysenski is a commercial pharmaceutical industry executive. She has more than 30 years of experience in the field and has been instrumental in launching several new products.

Wysenski attended Kent State University for her bachelor's degree in science and Baldwin Wallace College for her MBA. She has served on the boards of Tetraphase Pharmaceuticals, Alkermes PLC and the Healthcare Businesswomen’s Association, where she was also the founder and president of the Research Triangle Park Chapter.

Wysenski previously was the vice president of field sales at Astra Merck, Inc. and chief operating officer at Endo Pharmaceuticals. She was also the CEO and president of EMD Pharamceuticals from 2001 to 2006; and vice president of commercial at the company from 1999 to 2001. 

Wysenski has most recently held positions at Vertex Pharmaceuticals, where she served as the chief commercial officer and the executive vice president. While at Vertex, she led the company in creating its commercial infrastructure as well as the therapies Kalydeco and Incivek.

“Nancy brings to our board of directors her experience and judgment in growing a pharmaceutical business and launching new products,” Dr. Joseph J. Kim, the president and CEO of Inovio Pharmaceuticals, said. “Her counsel in these critical areas will support Inovio as we move our products closer to market."

Organizations in this Story


Want to get notified whenever we write about Inovio ?
Next time we write about Inovio, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.